InMed Pharmaceuticals (INM) Stock Price, News & Analysis

Company Overview

InMed Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of therapies based on rare cannabinoids. The company is developing pharmaceutical candidates intended to address diseases with significant unmet medical needs, using its proprietary IntegraSyn technology to support the production and formulation of cannabinoids.

InMed’s pharmaceutical pipeline has included INM-755, a topical cannabinol-based candidate being investigated for epidermolysis bullosa simplex, a rare genetic skin disorder. The company has also advanced INM-088, an eye-drop formulation designed for potential use in glaucoma. The development status of these programs may change as clinical and regulatory work progresses.

In addition to its pharmaceutical programs, InMed expanded into the commercial rare-cannabinoid ingredient market through its acquisition of BayMedica. That business develops and supplies rare cannabinoids, including ingredients for pharmaceutical, nutraceutical, health and wellness, and other commercial applications. InMed is headquartered in Vancouver, British Columbia, and its shares trade on Nasdaq under the symbol INM.

Key Stats

• Today's Range: $1.36 to $1.40
• 50-Day Range: $1.28 to $1.59
• 52-Week Range: $0.58 to $2.33
• Volume: 28,776 shs
• Average Volume: 64,612 shs
• Market Capitalization: $4.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

InMed Pharmaceuticals Stock Analysis - MarketRank™

InMed Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

InMed Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

InMed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of InMed Pharmaceuticals is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InMed Pharmaceuticals is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InMed Pharmaceuticals has a P/B Ratio of 4.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.04% of the float of InMed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.43, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InMed Pharmaceuticals has recently increased by 114.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InMed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

InMed Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.67

News Sentiment

InMed Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for InMed Pharmaceuticals this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $189,647.00 in company stock, which represents 4.2129% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, InMed Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $189,647.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.85% of the stock of InMed Pharmaceuticals is held by insiders.

Percentage Held by Institutions

20.12% of the stock of InMed Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 9/09/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INM
• CIK: 1728328
• Web: www.inmedpharma.com
• Phone: 604-669-7207
• Fax: N/A
• Employees: 6
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -156.08%
• Return on Assets: -123.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.37
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $4.94 million
• Price / Sales: 0.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.32 per share
• Price / Book: 4.25

Miscellaneous

• Outstanding Shares: 3,310,000
• Free Float: 3,286,000
• Market Cap: $4.50 million
• Optionable: Not Optionable
• Beta: 0.93